Free Trial
NASDAQ:RXRX

Recursion Pharmaceuticals Q2 2025 Earnings Report

Recursion Pharmaceuticals logo
$5.68 -0.27 (-4.54%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.62 -0.06 (-1.06%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

Recursion Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$15.38 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Recursion Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Recursion Pharmaceuticals Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Recursion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ:RXRX) operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Recursion Pharmaceuticals Profile

More Earnings Resources from MarketBeat